8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo
View todays social media effects on EPZM
View the latest stocks trending across Twitter. Click to view dashboard
See who Epizyme is hiring next, click here to view
